
OPKO Health (OPK) Stock Forecast & Price Target
OPKO Health (OPK) Analyst Ratings
Bulls say
OPKO Health Inc. reported a significant 20% growth in volumes for its 4Kscore test, contributing to a 5.3% increase in revenue within the non-oncology segment of its lab business. Furthermore, BARDA-related revenue rose to $8.2 million, reflecting a positive trajectory for the company’s pharmaceutical products segment, with ongoing expectations for margin improvements and operational enhancements in the diagnostics area. The company’s EPS also demonstrated resilience, reporting $0.03, supported by a one-time gain from a lab business divestiture, indicating an expansion in its overall operational activity and potential for future growth.
Bears say
OPKO Health's recent financial performance reflects significant challenges, particularly in its diagnostics segment, which recorded an $18.3 million operating loss for the quarter. Additionally, Q3 revenue fell short of expectations and was negatively impacted by lower gross margins and elevated operating expenses, leading to a disappointing fiscal year 2026 financial guidance. The pharmaceutical segment also faced setbacks, with product revenue declining to $37.7 million, primarily due to lower sales volumes and unfavorable product mix, further exacerbating the company's overall financial outlook.
This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.
OPKO Health (OPK) Analyst Forecast & Price Prediction
Start investing in OPKO Health (OPK)
Order type
Buy in
Order amount
Est. shares
0 shares